

# Clinical trials of statins for cardiovascular prevention in secondary prevention

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diet

Trial	Treatments	Patients	Trials design and methods
<b>diet vs usual diet</b>			
<b>DART (Burr) , 1989</b> n=NA follow-up: 2 years	diet advice versus usual diet	men who had recovered from MI	Factorial plan open, blind assessment

## References

### DART (Burr), 1989:

Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61 [2571009]

## 2 statins

Trial	Treatments	Patients	Trials design and methods
<b>atorvastatin vs placebo</b>			
<b>Mohler , 2003</b> n=NA follow-up: 12 months	atorvastatin (10 mg per day) versus placebo	patients with intermittent claudication	double blind
<b>fluvastatin vs placebo</b>			
<b>FLARE , 1999</b> n=409/425 follow-up: 40 weeks	fluvastatin 40 mg twice daily versus placebo	successful coronary balloon angioplasty	Parallel groups double blind
<b>LCAS , 1997</b> n=164/157 follow-up: 2.5 years	fluvastatin 20 mg twice daily versus placebo	men and women aged 35 to 75 years with angiographic CHD and mean low-density lipoprotein (LDL) cholesterol of 115 to 190 mg/dl despite diet	Parallel groups double-blind
<b>LIPS , 2002</b> n=844/833 follow-up: 3.9 years	fluvastatin, 80 mg/d versus placebo	patients (aged 18-80 years) with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 3.5-7.0 mmol/L and with fasting triglyceride levels of less than 4.5 mmol/L	Parallel groups double blind Europe, Canada, and Brazil
<b>Riegger et al. , 1999</b> n=187/178 follow-up: 1.0 years	fluvastatin 40 mg (o.a.d. or b.i.d.) versus placebo	hyperlipidaemic patients with symptomatic, clinically-diagnosed (exercise-ECG) coronary heart disease	Parallel groups double blind

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>lovastatin vs placebo</b>			
<b>ACAPS , 1994</b> [NCT00000469] n=460/459 follow-up: 2.8 years	lovastatin 20mg daily versus placebo	men and women, 40 to 79 years old, with early carotid atherosclerosis and moderately elevated LDL cholesterol.	Factorial plan double blind USA
<b>AFCAPS/TeXCAPS , 1998</b> n=3304/3301 follow-up: 5.2 years	lovastatin 20-40 mg/d versus placebo	men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levels	Parallel groups double blind USA
<b>CCAIT , 1994</b> n=165/166 follow-up: 2 years	lovastatin begun at 20 mg/d and titrated to 40 and 80 mg during the first 16 weeks to attain a fasting low-density lipoprotein (LDL) cholesterol $\leq$ 130 mg/dL versus placebo	patients with diffuse but not necessarily severe coronary atherosclerosis documented on a recent arteriogram and with fasting serum cholesterol between 220 and 300 mg/dL	Parallel groups double-blind Canada
<b>MARS , 1993</b> [NCT00116870] n=123/124 follow-up: 2.0y	lovastatin 80 mg/day versus placebo	patients, 37 to 67 years old, with total cholesterol ranging from 4.92 to 7.64 mmol/L (190 to 295 mg/dL) and angiographically defined coronary artery disease	Parallel groups double blind
<b>Weintraub , 1994</b> n=203/201 follow-up: 0.5 years	lovastatin 40 mg orally twice daily versus placebo	patients undergoing PTCA	Parallel groups double blind
<b>pravastatin vs placebo</b>			
<b>CARE , 1996</b> n=2081/2078 follow-up: 5 years	pravastatin 40 mg/d versus placebo	men and women with myocardial infarction who had plasma totalcholesterol levels below 240 mg per deciliter (mean,209) and low-density lipoprotein (LDL) cholesterollevels of 115 to 174 mg per deciliter	Parallel groups double blind USA, Canada
<b>LIPID , 1998</b> n=4512/4502 follow-up: 6.1 years	pravastatin 40 mg/d versus placebo	patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration of 4.0-7.0 mmol/L	Parallel groups double blind Australie et Nouvelle Zlande
<b>PACT , 2004</b> n=1710/1689 follow-up: 30 days	pravastatin initiated within 24 hours of onset of symptoms and for 4 weeks versus placebo	patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction $<$ 24 hours	Parallel groups double blind
<b>PLAC I , 1995</b> n=206/202 follow-up: 3 y	pravastatin 40mg daily versus placebo	men and women with coronary artery disease and mild to moderate elevations in cholesterol levels	Parallel groups double blind United States
<b>PLAC II , 1995</b> n=75/76 follow-up: 3 y	pravastatin 20-40mg daily versus placebo	coronary patients (men and women )	Parallel groups double blind United States

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>PROSPER , 2002</b> n=2891/2913 follow-up: 3.2 years	pravastatin 40mg daily versus placebo	men and women aged 70-82 years with a history of, or risk factors for, vascular disease	Parallel groups double blind Ecosse, Irlande, Pays bas
<b>REGRESS , 1995</b> n=450/435 follow-up: 2 years	pravastatin 40 mg daily versus placebo	symptomatic men with normal to moderately elevated serum cholesterol levels	Parallel groups double blind Netherlands
<b>simvastatin vs placebo</b>			
<b>4S , 1994</b> n=2221/2223 follow-up: 5.4 years	simvastatin 20 or 40 mg/d, target CT between 3 et 5.2 mmol/l versus placebo	patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet	Parallel groups double blind Scandinavia
<b>CIS , 1997</b> n=129/125 follow-up: 2.3 years	simvastatin 40 mg versus placebo	men with documented coronary artery disease and hypercholesterolaemia	Parallel groups double blind
<b>HPS , 2002</b> n=10269/10267 follow-up: 5 years	simvastatin 40 mg/d versus placebo	adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabete	Factorial plan double blind UK
<b>MAAS , 1994</b> n=193/188 follow-up: 4 y	simvastatin 20 mg daily versus placebo	patients with coronary heart disease	Parallel groups double blind
<b>atorvastatin vs usual care</b>			
<b>GREACE , 2002</b> n=800/800 follow-up: 3 years mean	atorvastatin 10-80 mg/d versus usual care	patients with established coronary heart disease	Parallel groups open
<b>lovastatin vs usual care</b>			
<b>CLAPT , 1999</b> n=112/114 follow-up: 2.0 years	lovastatin begun at 20 mg daily and tritrated up to 80 mg daily versus usual care	patients undergoing PTCA	Parallel groups open (blind assesement)
<b>Sahni , 1991</b> n=79/78 follow-up: 2 years	lovastatin 20-40mg/d versus conventional therapy alone	patients undergoing successful PTCA	Parallel groups open
<b>pravastatin vs usual care</b>			
<b>GISSI Prevenzione , 2000</b> n=2138/2133 follow-up: 23 months (mean)	low-dose pravastatin regimen 20 mg daily versus control	recent acute myocardial infarction patients (<= 6 months) with total blood cholesterol >= 200 mg/dl and <250 mg/dl and after a period of 36 months showed plasma cholesterol levels >=200 mg/ dL despite adequate dietary recommendations	Parallel groups open Italy

## References

Mohler, 2003:

Mohler ER 3rd, Hiatt WR, Creager MA Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation* 2003;108:1481-6 [12952839]

**FLARE, 1999:**

Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. *Eur Heart J* 1999;20:58-69 [10075142]

**LCAS, 1997:**

Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, Gould KL, Gotto AM Jr Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). *Am J Cardiol* 1997;80:278-86 [9264419]

**LIPS, 2002:**

Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002; 287:3215-22 [12076217]

**Riegger et al., 1999:**

Riegger G, Abletshauer C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, Welzel D The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. *Atherosclerosis* 1999;144:263-70 [10381299]

**ACAPS, 1994:**

Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. *Circulation* 1994;90:1679-87 [7734010]

Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. *Control Clin Trials* 1992;13:293-314 [1330434]

**AFCAPS/TexCAPS, 1998:**

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998; 279:1615-22 [9613910]

Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, Clearfield MB Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). *Am J Cardiol* 2009;104:829-34 [19733719]

**CCAIT, 1994:**

Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. *Am J Cardiol* 1995;76:47C-53C [7572686]

Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Lesprance J Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada. *Control Clin Trials* 1993;14:45-74 [8440094]

Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesprance J Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. *Circulation* 1994;89:959-68 [8124836]

**MARS, 1993:**

Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). *Ann Intern Med* 1993;119:969-76 [8214993]

**Weintraub, 1994:**

Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. *N Engl J Med* 1994;331:1331-7 [7935702]

**CARE, 1996:**

Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996; 335:1001-9 [8801446]

Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moy LA, Piller LB, Rutherford J, Simpson LM, Braunwald E Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. *Circulation* 1999;99:216-23 [9892586]

#### **LIPID, 1998:**

, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998; 339:1349-57 [9841303]

, Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. *Lancet* 2002; 359:1379-87 [11978335]

Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. *Am J Cardiol* 1995;76:474-9 [7653447]

#### **PACT, 2004:**

Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. *Am Heart J* 2004;148:e2 [15215811]

#### **PLAC I, 1995:**

Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. *Am J Cardiol* 1995;76:60C-63C [7572689]

Pitt B, Ellis SG, Mancini GB, Rosman HS, McGovern ME Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). *Am J Cardiol* 1993;72:31-5 [8517425]

Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. *J Am Coll Cardiol* 1995;26:1133-9 [7594023]

#### **PLAC II, 1995:**

Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol* 1995;76:54C-59C [7572688]

Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M, Furberg CD Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. *Control Clin Trials* 1992;13:495-506 [1334821]

Furberg CD, Byington RP, Crouse JR, Espeland MA Pravastatin, lipids, and major coronary events. *Am J Cardiol* 1994;73:1133-4 [8198043]

#### **PROSPER, 2002:**

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360:1623-30 [12457784]

#### **REGRESS, 1995:**

Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). *Circulation* 1995;91:2528-40 [7743614]

van Boven AJ, Jukema JW, Zwinderman AH, Crijs HJ, Lie KI, Bruschke AV Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. *Circulation* 1996;94:1503-5 [8840836]

#### **4S, 1994:**

, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) *Lancet* 1994; 344:1383-9 [7968073]

#### **CIS, 1997:**

Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeit K, Blmchen G, Claus J, Mathes P, Kappenberger L, Wieland H, Neiss A The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34 [9043838]

**HPS, 2002:**

, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22 [12114036]  
 Armitage J, Collins R Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart 2000;84:357-60 [10995396]

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41 [10329064]

**MAAS, 1994:**

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 1994;344:633-8 [7864934]

**GREACE, 2002:**

Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8 [12201623]

**CLAPT, 1999:**

Kleemann A, Eckert S, von Eckardstein A, Lepper W, Schernikau U, Gleichmann U, Hanrath P, Fleck E, Neiss A, Kerber S, Assmann G, Breithardt and the CLAPT Study Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT) Eur Heart J 1999;20:1393-406 [10487800]

**Sahni, 1991:**

Sahni R, Maniet AR, Voci G, Banka VS Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-8 [2035374]

**GISSI Prevenzione, 2000:**

### 3 statins high dose

Trial	Treatments	Patients	Trials design and methods
<b>atorvastatin high dose vs angioplasty</b>			
<b>AVERT , 1999</b> n=164/177 follow-up: 1.5 years	atorvastatin 80 mg/d versus recommended percutaneous revascularization procedure(angioplasty) followed by usual care, which could include lipid-lowering treatment	patients referred for percutaneous revascularization, with stable coronary artery disease, relatively normal left ventricular function, asymptomatic or mild-to-moderate angina, and a serum level of low-density lipoprotein (LDL) cholesterol of at least 115 mg per deciliter (3.0 mmol per liter)	Parallel groups open US, Europe
<b>atorvastatin high dose vs atorvastatin</b>			
<b>TNT , 2005</b> [NCT00327691] n=4995/5006 follow-up: 4.9 years	80 mg of atorvastatin daily versus 10 mg of atorvastatin daily	Chronic coronary artery disease LDL cholesterol <3.4 mmol/L	Parallel groups double blind 14 countries
<b>atorvastatin high dose vs lovastatin</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Vascular basis , 2005</b> n=197/103 follow-up: 1 year	atorvastatin (80 mg) with or without vitamin C and E versus low dose lovastatin (5 mg)	Chronic coronary artery disease	Parallel groups double blind
<b>atorvastatin high dose vs pravastatin</b>			
<b>REVERSAL , 2004</b> n=327/327 follow-up: 1.5 years	atorvastatin 80 mg daily versus Pravastatin(40 mg)	Chronic coronary artery disease	Parallel groups double blind
<b>SAGE , 2007</b> n=446/445 follow-up: 1 years	atorvastatin 80 mg daily versus pravastatin(40 mg)	Chronic coronary artery disease	Parallel groups double blind
<b>atorvastatin high dose vs simvastatin</b>			
<b>IDEAL , 2005</b> [NCT00159835] n=4439/4449 follow-up: 4.8 years	atorvastatin 80mg daily versus simvastatine 20mg/j	Men and women aged 80 years or younger with a history of a definite myocardial infarction and who qualified for statin therapy according to national guidelines	Parallel groups open Denmark, Finland, Iceland, Netherlands, Norway, Sweden
<b>simvastatin high dose vs simvastatin</b>			
<b>SEARCH , 2010</b> [NCT00124072] n=6031/6033 follow-up: 6.7 years (mean)	simvastatin 80 mg daily versus simvastatin 20mg daily	MI survivors	Parallel groups

## References

**AVERT, 1999:**

**TNT, 2005:**

**Vascular basis, 2005:**

**REVERSAL, 2004:**

**SAGE, 2007:**

**IDEAL, 2005:**

**SEARCH, 2010:**

## 4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.